[Fluorodopa PET scanning in Parkinson’s disease]

Groppo J, Bardach A, Colaci C, Alfie V, Ciapponi A, Augustovski F, García Martí S, Alcaraz A, Pichon-Riviere A
Record ID 32018004411
Original Title: PET con fluorodopa en enfermedad de Parkinson
Authors' recommendations: No  studies  assessing  the  therapeutic  impact  and  safety  of  Fluorodopa  Positron  Emission Tomography (PET) Scanning in Parkinson’s disease as an outcome have been found.  Low‐quality  evidence  suggests  that  fluorodopa  PET  scanning  in  Parkinson’s  disease might  result in a marginal diagnostic performance increase in differentiating essential tremor but  not with other degenerative parkinsonisms. Most clinical practice guidelines consulted do  not mention the routine use of this technology to diagnose Parkinson’s disease, except for one guideline  from Spain where it is mentioned in differential diagnosis of parkinsonisms.  The health funders consulted do not include fluorodopa PET scanning among their coverage  policies for this condition. 
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Parkinson Disease
  • Levodopa
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Diagnostic Imaging
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.